Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
Body unavailable. Use the original source.
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test